



NDI is disrupting the stagnant healthcare market with a revolutionary technology that captures, refines, and redistributes medical data.

The Problem

Healthcare industry is stagnant with innovation - Medical data is a highly valuable asset that is underutilized

The Idea

Disrupt this broken system to capture, analyze and distribute medical data to drive innovation elevate healthcare

The Opportunity

Create an ecosystem where medical data is refined and monetized in new financial markets

The Solution

NDI has created a non-intrusive patent-pending collection procedure for surgery centers using customized bar-coded scanning technology.


This real-time data process will capture:
Sales Data - Usage Data - Outcome Data
Pharmaceutical Usage - Insurance Data
Patient Satisfaction Data

Competition

NDI has identified several small competitors but none are able to offer:


- Product sales data
- Data across multiple specialties
- Patient satisfaction data over time
- Patient comorbidity trending

Customers: 12 customer verticals identified to purchase data



Big Data will represent a **\$210 Billion** market by 2020*

Strategic Partners:



Leadership Team

David Watts, MD

Chairman, Board of Directors
and Chief Executive Officer

Larry Reed, MD

Vice Chairman, Board of Directors

Samuel Lin, MD

Director of Research

Lisa Stichert

Chief Operating Officer

Jeffrey Mazza

Director of Finance

Nebula Data Intel, LLC

Employees: 20 and growing

Advisors

Jack Bouroudjian

Chief Economist, UCX, LLC

Silvana Da Luca

Chief Operating Officer, Blockchain
& Crypto Markets, PCG Advisory

Doug Gisby

Chief Technology Officer, UCX, LLC

Jeff Hood

Co-Founder, BlockSquared

Jeff Ramson

Founder & CEO, PCG Advisory

Ryan Ripa

VP of Product Management and
Technical Sales, UCX, LLC

Jim Valentine

Executive Director, Driehaus Center
for Behavioral Finance

Adam Zeck

CEO, UCX, LLC


Ascendant Capital, LLC

PCG Advisory Group

UCX, LLC

Willis Towers Watson

Sales Plan - Monetizing the data



- Data can be purchased raw for companies to analyze in house.
- Data can be sold packaged with options of AI/ML integration and external data can be purchased to supplement the portfolio.
- Data sold as commodity on the CME or ICE exchange allowing for fees from derivatives to be collected.

PROFORMA P&L	2019	2020	2021	2022	2023	2024
Revenue						
Total revenue	3,250,000	19,750,000	39,000,000	70,250,000	122,500,000	210,000,000
Sales Growth		508%	97%	80%	74%	71%
Cost of sales	5,350,000	8,295,000	16,380,000	29,505,000	51,450,000	88,200,000
Adjusted Gross Revenue	(2,100,000)	11,455,000	22,620,000	40,745,000	71,050,000	121,800,000
Expenses						
Total operating expenses	14,020,000	21,331,000	32,002,525	36,612,676	42,842,835	51,592,027
EBITDA	(16,120,000)	(9,876,000)	(9,382,525)	4,132,324	28,207,165	70,207,973

This proforma P&L statement includes projections, forecasts and other predictive statement that represent Nebula Data Intel, LLC assumptions and expectations in light of currently available information. These forecasts, etc. are based on industry trends, circumstances involving clients and other factors and that involve risks, variables and uncertainties. Nebula's actual performance results may differ from those projected in the proforma P&L statement. Consequently, no guarantee is presented or implied as the accuracy of specific forecasts, projections or predictive statements contained herein.